Mark Cunningham is responsible for strategic and operational activities across the Immunology Therapeutic Area. This includes optimizing internal business practices, managing the execution of external science and enabling decisions at the portfolio level. Since joining the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor Research & Development in 2001, Mark has leveraged years of experience in scientific research, business planning and project management to drive excellence in drug discovery and development by embracing technology and supporting collaboration without boundaries.
Immunology